ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe DOTS trial demonstrated similar clinical outcomes among 200 adults with complicated Staphylococcus aureus bacteremia (SAB) randomized to two doses of dalbavancin or standard-therapy antibiotics after initial clearance. We aimed to determine whether the higher cost of dalbavancin is offset through reductions in medical resource use.
methodsWe used dates for hospitalizations and antibiotics from the trial starting from randomization. Antibiotic costs were based on generic pricing for dalbavancin and most other antibiotics. Medicare payment rates were used to estimate costs for scenarios representing home-based or clinic-based outpatient antibiotic therapy (OPAT).
resultsOn average, patients randomized to dalbavancin spent 2.2 fewer SAB-related days in the hospital (95%CI: -5.3 to 1.3) and received antibiotics on 24.4 fewer days (95%CI: -29.0 to -19.9). Mean inpatient costs for SAB-related admissions were lower by $5805 (95%CI: -14,311 to 3390) in the dalbavancin group. Antibiotic drug costs were $2343 higher (95%CI: 1728 to 3027), but OPAT costs were lower with dalbavancin by $2469 (95% CI: -2913 to -1970) in the home-based scenario and $1112 (95% CI: -1289 to -914) in the clinic-based scenario. Net costs for SAB-related care were $5931 lower (95%CI: -14,660 to 3004) and $4574 lower (95%CI: -13,312 to 4335) with dalbavancin versus standard-therapy with home-based and clinic-based OPAT, respectively. Among patients with injection drug use (IDU), savings with dalbavancin were approximately $22,000.
conclusionsOn average, savings from reduced inpatient care and less OPAT fully offset the higher cost of dalbavancin in patients with SAB. Savings were greater in patients with IDU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.